Evolus, Inc. (EOLS) News

Evolus, Inc. (EOLS): $12.05

-0.28 (-2.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter EOLS News Items

EOLS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EOLS News Highlights

  • EOLS's 30 day story count now stands at 10.
  • Over the past 29 days, the trend for EOLS's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • TGA, VRTX and BEAT are the most mentioned tickers in articles about EOLS.

Latest EOLS News From Around the Web

Below are the latest news stories about Evolus Inc that investors may wish to consider to help them evaluate EOLS as an investment opportunity.

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 24, 2022

Evolus to Report Fourth Quarter and Year End 2021 Results and Provide Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that it will report its fourth quarter and year end 2021 financial results and provide a business update on Thursday, March 3, 2022.

Business Wire | February 17, 2022

Evolus (EOLS) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | February 17, 2022

Evolus'' request to market anti-wrinkle therapy accepted in Australia

Evolus <> announced on Tuesday that the Australian Therapeutics Good Administration ((TGA)) accepted its submission seeking the regulatory approval of Nuceiva

Seeking Alpha | February 8, 2022

Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva®

NEWPORT BEACH, Calif., February 08, 2022--Evolus announces the acceptance of its submission to the Australian Therapeutics Good Administration for regulatory approval of Nuceiva®

Yahoo | February 8, 2022

Evolus to Participate in the Virtual 11th Annual SVB Leerink Global Healthcare Conference

NEWPORT BEACH, Calif., February 02, 2022--Evolus announces that members of its management team will be participating in the Virtual 11th Annual SVB Leerink Global Healthcare Conference.

Yahoo | February 2, 2022

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Evolus (EOLS)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX – Research Report) and Evolus (EOLS – Research Report) with bullish sentiments. Vertex Pharmaceuticals (VRTX) H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals today and set a price target of $275.00. The company's shares closed last Wednesday at $226.58. According to TipRanks.

Catie Powers on TipRanks | January 27, 2022

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance

NEWPORT BEACH, Calif., January 26, 2022--Evolus announces its preliminary, unaudited net revenue and cash position as of and for the fourth quarter and full-year ended December 31, 2021.

Yahoo | January 26, 2022

Evolus on the rise after Truist upgraded on prospects for wrinkles treatment

Evolus <> has recorded the biggest intraday gain in more than three months after Truist upgraded the Pharma company to Buy from Hold, citing its performance in the Jeuveau launch

Seeking Alpha | January 20, 2022

HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ...

Stockholm, V7, based Investment company HealthInvest Partners AB (Current Portfolio) buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Bristol-Myers Squibb Co, AbbVie Inc, sells Supernus Pharmaceuticals Inc, Accuray Inc, Aldeyra Therapeutics Inc, Rigel Pharmaceuticals Inc, Evolus Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HealthInvest Partners AB.

Yahoo | January 18, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7381 seconds.